why choose us

First received: June 23, 2023

Clinical Trial: Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes

Study Status: Completed

Recruit Status: RECRUITING

Condition: Myelodysplastic Syndromes

Study Type: INTERVENTIONAL


Official Title: A Phase I/II Trial of Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes

Brief Summary: Background:Myelodysplastic syndromes (MDS) are diseases that affect the bone marrow.They can inhibit the blood formation process and reduce blood cell counts.High-risk MDS can lead to leukemia.People with high-risk MDS have a low survival rate.Better treatments are needed.Objective:To test a study drug (KPT-8602), combined with another drug (Inqovi), in people with MDS.Eligibility:Adults aged 18 years and older with high-risk MDS that did not respond to treatment.Design:Participants will be screened.They will have…

Read more